Article
Medicine, General & Internal
Eon Jeong Nam, Won Kee Lee
Summary: This study examined the likelihood of achieving clinical remission in patients with ankylosing spondylitis receiving tumor necrosis factor-alpha inhibitors. Age and improvement in disease activity markers within three months were identified as independent predictors of achieving clinical remission.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Cristina Fernandez-Carballido, Vega Jovani, Emma Beltran Catalan, Manuel Jose Moreno-Ramos, Jesus Sanz Sanz, Adela Gallego, M. Luz Garcia Vivar, Jose Manuel Rodriguez-Heredia, Cristina Sanabra, Carlos Sastre
Summary: This study revealed a higher proportion of females with active disease among AS patients using BASDAI definition, while the impact of disease activity on health status appears to be more significant in females compared to males.
FRONTIERS IN MEDICINE
(2022)
Article
Rheumatology
Oh Chan Kwon, Min-Chan Park
Summary: This study determined the cut-off values of BASDAI for determining disease activity states in ankylosing spondylitis patients. The study found that BASDAI values of 1.9, 3.5, and 4.9 corresponded to ASDAS-CRP values of 1.3, 2.1, and 3.5, respectively. The agreement between disease activity states based on BASDAI and ASDAS-CRP cut-off values was good.
Article
Rheumatology
Reinder Raadsen, Romy Hansildaar, Lianne C. Pouw, Femke Hooijberg, Laura Boekel, Gerrit Jan Wolbink, Arno W. R. van Kuijk, Michael T. Nurmohamed
Summary: This study evaluates the cardiovascular disease risk and prevalence of risk factors in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (SpA). The results show that the traditional cardiovascular risk factors are significantly elevated in these patients compared to healthy controls. However, after adjusting for traditional risk factors, the cardiovascular risk was not increased in these patients.
Article
Rheumatology
Mark C. Hwang, MinJae Lee, Lianne S. Gensler, Matthew A. Brown, Amirali Tahanan, Mohammad H. Rahbar, Theresa Hunter, Mingyan Shan, Mariko L. Ishimori, John D. Reveille, Michael H. Weisman, Thomas J. Learch
Summary: This study identified four distinct patterns of spinal disease progression in ankylosing spondylitis patients. Factors associated with higher spinal disease burden groups include male gender, longer disease duration, elevated CRP and smoking history. Independent confirmation in other AS cohorts is needed to confirm these radiographic patterns.
Article
Rheumatology
Augusta Ortolan, Sofia Ramiro, Roberta Ramonda, Desiree van der Heijde
Summary: The altASDAS index is a valid tool for assessing disease activity in axial SpA patients when patient global assessment is unavailable. It has been shown to be both truthful and discriminative in an external cohort, demonstrating its usefulness in clinical practice.
Article
Orthopedics
Bora Nam, Bon San Koo, Tae-Han Lee, Ji-Hui Shin, Jin-Ju Kim, Seunghun Lee, Kyung Bin Joo, Tae-Hwan Kim
Summary: A significant proportion of AS patients with low BASDAI scores were found to have high ASDAS-CRP, indicating higher disease activity and increased risk of discontinuing anti-TNF treatment due to lack/loss of efficacy compared to those with low ASDAS. The use of ASDAS-CRP alone or in conjunction with BASDAI may enhance the evaluation of AS patients treated with anti-TNF agents.
BMC MUSCULOSKELETAL DISORDERS
(2021)
Article
Medicine, Research & Experimental
Vladiana Turi, Stela Iurciuc, Octavian Marius Cretu, Delia Mirela Tit, Simona Bungau, Adrian Apostol, Radu Dumitru Moleriu, Cristiana Bustea, Tapan Behl, Camelia Cristina Diaconu, Izabella Petre
Summary: The study revealed significant differences in hemodynamic and arterial stiffness parameters as well as heart rate between pregnant women with hypertension and those without. Arterial function parameters in women with pregnancy-induced hypertension differed long before the onset of high blood pressure, and body mass index had a deleterious effect, especially in pregnant women with hypertension. The assessment of arterial function parameters and BMI is important for predicting future blood pressure values and outcomes during pregnancy.
Article
Rheumatology
Jean W. Liew, S. Reza Jafarzadeh, Maureen Dubreuil, Susan R. Heckbert, Stephen J. Mooney, Matthew A. Brown, Mariko L. Ishimori, John D. Reveille, Michael M. Ward, Michael H. Weisman, Lianne S. Gensler
Summary: This study found no significant association between TNFi use and incident hypertension in a longitudinal cohort of patients with ankylosing spondylitis.
JOURNAL OF RHEUMATOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Shiyun Luo, Yawen Zhao, Shanshan Zhu, Ludi Liu, Ken Cheng, Bingqi Ye, Yueyuan Han, Jiahua Fan, Min Xia
Summary: This study compares the microbiota composition and metabolic capacities between patients with elevated arterial stiffness and normal controls. It identifies a protective bacterium called F plautii, which plays a role in improving arterial function and reducing arterial stiffness by increasing the level of cis-aconitic acid. This research provides a new approach to maintaining vascular health by regulating gut microbiota.
CIRCULATION RESEARCH
(2023)
Article
Immunology
Jin-Xian Huang, Yung-Heng Lee, James Cheng-Chung Wei
Summary: Ankylosing spondylitis (AS) is associated with increased risk of cardiovascular disease (CVD), and tumor necrosis factor inhibitors (TNFi) may be effective in treating this risk. However, the impact of TNFi on lipid changes and atherosclerosis is still controversial.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Eric Toussirot
Summary: Patients with axial spondyloarthritis (axSpA) have an increased cardiovascular risk, which may be attributed to various factors including traditional risk factors, inflammation, and medication use. More research is needed, especially in patients with non-radiographic form of axSpA, to assess cardiovascular comorbidities.
FRONTIERS IN MEDICINE
(2021)
Article
Rheumatology
Fabian Proft, Julia Schally, Henning Christian Brandt, Jan Brandt-Juergens, Gerd Ruediger Burmester, Hildrun Haibel, Henriette Kaeding, Kirsten Karberg, Susanne Lueders, Burkhard Muche, Mikhail Protopopov, Judith Rademacher, Valeria Rios Rodriguez, Murat Torgutalp, Maryna Verba, Silke Zinke, Denis Poddubnyy
Summary: The study aimed to validate the Ankylosing Spondylitis Disease Activity Score (ASDAS) using a quick quantitative C-reactive protein (qCRP) assay in patients with axial spondyloarthritis. Results showed an almost perfect agreement between ASDAS-Q and ASDAS-CRP in assigning disease activity categories.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
(2022)
Article
Immunology
Kathy Ming Feng, Wu-Chien Chien, Yi-Hao Chen, Chien-An Sun, Chi-Hsiang Chung, Jiann-Torng Chen, Ching-Long Chen
Summary: This study found that uveitis could be a predictor of ACS in patients with AS. Both anterior uveitis and posterior segment involvement were associated with an increased risk of ACS in AS patients. Age, diabetes mellitus, hypertension, hyperlipidemia, chronic obstructive pulmonary disease, asthma, and systemic steroids were significant risk factors for ACS. The all-cause mortality was higher in the uveitis group compared to the non-uveitis group.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Yi-Fen Lai, Ting-Yi Lin, Wu-Chien Chien, Chien-An Sun, Chi-Hsiang Chung, Yi-Hao Chen, Jiann-Torng Chen, Ching-Long Chen
Summary: This study found that patients with AS who have uveitis are at a significantly higher risk of developing acute myocardial infarction (AMI) compared to those without uveitis. Regardless of gender or age group, patients with uveitis in the AS population have an increased risk for AMI.
FRONTIERS IN IMMUNOLOGY
(2022)
Letter
Rheumatology
Anna Molto, Desiree van der Heijde, Filip E. van den Bosch, Maxime Dougados
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Ricardo J. O. Ferreira, Paco M. J. Welsing, Johannes W. G. Jacobs, Laure Gossec, Mwidimi Ndosi, Pedro M. Machado, Desiree van der Heijde, Jose A. P. Da Silva
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Desiree van der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew A. Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M. Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S. Gensler, Nigil Haroon, Marina Magrey, Walter P. Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip van den Bosch, Thomas Vaux, Huji Xu
Summary: The BE MOBILE 1 and BE MOBILE 2 trials demonstrated that bimekizumab, a dual IL-17A and IL-17F inhibitor, improved efficacy outcomes in patients with axial spondyloarthritis (axSpA) and was well tolerated. These findings support the use of bimekizumab as a potential treatment option for axSpA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Robert B. M. Landewe
Summary: This study aimed to update the evidence on the efficacy of DMARDs and provide information for the 2022 update of EULAR recommendations for RA management. A systematic literature review was conducted to investigate the efficacy of cs, b, biosimilar, and tsDMARDs in RA patients. The results showed that csDMARDs combined with short-term glucocorticoids in early RA were as effective as bDMARD+MTX combination therapy. JAK inhibitors were effective in different patient populations. Tapering of DMARDs was feasible for some patients who could maintain low disease activity or achieve remission.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher J. Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja Stamm, Jan W. Schoones, Robert B. M. Landewe
Summary: This study conducted a systematic literature review (SLR) to evaluate the safety of synthetic and biological disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA). The results indicated that bDMARDs were associated with an increased risk of serious infections compared to csDMARDs, while JAK inhibitors (JAKi) showed higher risk of herpes zoster infections. The risks of malignancies, major adverse cardiovascular events (MACE), and venous thromboembolism (VTE) were similar among different treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Josef S. Smolen, Robert B. M. Landewe
Summary: This systematic literature review examines the efficacy, duration of use, and safety of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA). The study confirms the effectiveness of GCs in treating RA, with most patients able to stop GCs within 12-24 months. However, the use of GCs also carries well-known safety risks, including osteoporotic fractures, serious infections, diabetes, and mortality.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Pharmacology & Pharmacy
Vida Terzic, Lea Levoyer, Melanie Figarella, Elisabetta Bigagli, Noemie Mercier, Lucie De Gastines, Severine Gibowski, Marius Troseid, Jacques Demotes, Inge Christoffer Olsen, Maya Hites, Florence Ader, Jose Ramon Arribas Lopez, France Mentre, Helene Esperou, Dominique Costagliola, John-Arne Rottingen, Julien Poissy, Jean-Christophe Roze, Adilia Warris, Jackie O'Leary, Ricardo M. Fernandes, Lambert Assoumou, Regis Hankard, Mark A. Turner, Yazdan Yazdanpanah, Alpha Diallo
Summary: To ensure the safety of participants and regulatory compliance in academic trials, a centralized pharmacovigilance system was established, allowing sponsors to delegate work. This system consisted of key procedures, a local safety officer network, and centralized safety activities. Lessons learned from four trials demonstrated the ability to manage diverse European requirements and communicate effectively with trial teams.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Rheumatology
Sofia Ramiro, Robert Landewe, Desiree van der Heijde, Alexandre Sepriano, Oliver FitzGerald, Mikkel Ostergaard, Joanne Homik, Ori Elkayam, J. Carter Thorne, Maggie J. Larche, Gianfranco Ferraccioli, Marina Backhaus, Gilles Boire, Bernard Combe, Thierry Schaeverbeke, Alain Saraux, Maxime Dougados, Maurizio Rossini, Marcello Govoni, Luigi Sinigaglia, Alain G. Cantagrel, Cornelia F. Allaart, Cheryl Barnabe, Clifton O. Bingham III, Dirkjan van Schaardenburg, Hilde B. Hammer, Rana Dadashova, Edna Hutchings, Joel Paschke, Walter P. Maksymowych
Summary: The study investigates whether meticulously following a treat-to-target (T2T) strategy in daily clinical practice leads to less radiographic progression in patients with active rheumatoid arthritis (RA). The findings show that a more stringent application of T2T does not result in less radiographic progression compared to a somewhat lenient attitude towards T2T.
Article
Medicine, General & Internal
Liv Cathrine Heggebo, Ida Maria Henriksen Borgen, Hillevi Rylander, Cecilie Kiserud, Tonje Haug Nordenmark, Taran Paulsen Hellebust, Morten Egeberg Evensen, Magnus Gustavsson, Christina Ramberg, Mette Sprauten, Henriette Magelssen, Hanne Blakstad, Janani Moorthy, Karin Andersson, Ingela Raunert, Thomas Henry, Cecilie Moe, Carin Granlund, Dorota Goplen, Jorunn Brekke, Tor-Christian Aase Johannessen, Tora Skeidsvoll Solheim, Kirsten Marienhagen, Oyvind Humberset, Per Bergstrom, Mans Agrup, Ludvig Dahl, Michael Gubanski, Helene Gojon, Carl-Johan Brahme, Isabelle Ryden, Asgeir S. Jakola, Einar O. Vik-Mo, Hanne C. Lie, Lars Asphaug, Maziar Hervani, Ingrid Kristensen, Corina Silvia Rueegg, Inge C. Olsen, Rolf J. Ledal, Eskil Degsell, Katja Werlenius, Malin Blomstrand, Petter Brandal
Summary: This study is an open-label, multicenter, randomized phase III non-inferiority study comparing proton therapy and photon therapy in the treatment of IDH-mutated diffuse gliomas grade 2-3. The results of this study will provide important information on the safety, cognition, fatigue, and quality of life parameters for this patient population.
Article
Rheumatology
Rosalinde Stal, Sofia Ramiro, Xenofon Baraliakos, Juergen Braun, Monique Reijnierse, Rosaline van den Berg, Desiree van der Heijde, Floris A. van Gaalen
Summary: The objective of this study was to assess the construct validity of the CT Syndesmophyte Score (CTSS) for measuring structural spinal damage in patients with radiographic axial spondyloarthritis. The study compared the scores of CTSS and modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) in detecting syndesmophytes and their correlation with spinal mobility. The results demonstrated good agreement between CTSS and mSASSS in detecting syndesmophytes, and higher correlation of CTSS with spinal mobility measures.
Article
Rheumatology
Mary Lucy Marques, Nuno Pereira da Silva, Desiree van der Heijde, Rosalinde Stal, Xenofon Baraliakos, Juergen Braun, Monique Reijnierse, Caroline Bastiaenen, Sofia Ramiro, Floris A. van Gaalen
Summary: The study investigated the association between inflammation and lower trabecular bone density (TBD) in radiographic axial spondyloarthritis (r-axSpA), and whether a lower TBD increases the likelihood of 2-year bone formation at the same vertebra. The study found that inflammation was associated with lower TBD, but lower TBD itself did not increase the risk of new bone formation at the same vertebra.
Letter
Biochemistry & Molecular Biology
Erica Telford, Beatriz Grinsztejn, Inge Christoffer Olsen, Nicolas Pulik, France Mentre, Skerdi Haviari, Maxime Hentzien, Olivier Segeral, Miquel B. Ekkelenkamp, Dimie Ogoina, Nathalie Strub-Wourgaft, Alpha Diallo, Yazdan Yazdanpanah, Alexandra Calmy
Article
Critical Care Medicine
Marius Troseid, Jose R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzic, Fulvia Mazzaferri, Jesus Rodriguez Bano, Joe Eustace, Maya Hites, Michael Joannidis, Jose-Artur Paiva, Jean Reuter, Isabel Puentmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Borresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltan Peterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Unal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Moller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Balde, Lucie de Gastines, Marta del Alamo, Burc Aydin, Fridtjof Lund-Johansen, Mary-Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Rottingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola
Summary: The study conducted a placebo-controlled trial of baricitinib in severe/critical COVID cases. The results showed that baricitinib did not reduce mortality within 60 days, and there may be safety risks in vaccinated participants, which require further investigation.
Review
Critical Care Medicine
Alain Amstutz, Benjamin Speich, France Mentre, Corina Silvia Rueegg, Drifa Belhadi, Lambert Assoumou, Charles Burdet, Srinivas Murthy, Lori Elizabeth Dodd, Yeming Wang, Kari A. O. Tikkinen, Florence Ader, Maya Hites, Maude Bouscambert, Mary Anne Trabaud, Mike Fralick, Todd C. Lee, Ruxandra Pinto, Andreas Barratt-Due, Fridtjof Lund-Johansen, Fredrik Mueller, Olli P. O. Nevalainen, Bin Cao, Tyler Bonnett, Alexandra Griessbach, Ala Taji Heravi, Christof Schonenberger, Perrine Janiaud, Laura Werlen, Soheila Aghlmandi, Stefan Schandelmaier, Yazdan Yazdanpanah, Dominique Costagliola, Inge Christoffer Olsen, Matthias Briel
Summary: This systematic review and meta-analysis assessed the benefits and harms of remdesivir compared to placebo or usual care in COVID-19 patients hospitalized. The study found that remdesivir reduced mortality in patients who required no or conventional oxygen support but did not have enough evidence for patients on ventilators.
LANCET RESPIRATORY MEDICINE
(2023)
Letter
Rheumatology
Valeriia Melokhina, Nina Paulshus Sundlisaeter, Joseph Sexton, Ulf Sundin, Anna-Birgitte Aga, Kaja E. Kjorholt, Lena Bugge Nordberg, Desiree van der Heijde, Espen Haavardsholm, Siri Lillegraven
ANNALS OF THE RHEUMATIC DISEASES
(2023)